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In May 2003, the World Health Organization received
reports about a possible outbreak of a hemorrhagic disease
of unknown cause in the Imatong Mountains of southern
Sudan. Laboratory investigations were conducted on 28
serum samples collected from patients in the Imatong
region. Serum samples from 13 patients were positive for
immunoglobulin M antibody to flavivirus, and serum sam-
ples from 5 patients were positive by reverse transcrip-
tion–polymerase chain reaction with both the genus
Flavivirus-reactive primers and yellow fever virus–specific
primers. Nucleotide sequencing of the amplicons obtained
with the genus Flavivirus oligonucleotide primers confirmed
yellow fever virus as the etiologic agent. Isolation attempts
in newborn mice and Vero cells from the samples yielded
virus isolates from five patients. Rapid and accurate labo-
ratory diagnosis enabled an interagency emergency task
force to initiate a targeted vaccination campaign to control
the outbreak.
Y
ellow fever virus (YFV), an arthropod-borne virus in
the genus Flavivirus of the family Flaviviridae, is the
etiologic agent of yellow fever, a viral hemorrhagic fever
that occurs in South American countries and much of sub-
Saharan Africa (1,2). Flaviviruses are single-stranded, pos-
itive-sense RNA viruses with a genome organization of
5′-C, prM, M, E, NS1, NS2A, NS2B, NS3, NS4A, 2K,
NS4B, and NS5-3′ (3,4). YFV is transmitted by the bite of
an infected female mosquito, usually Aedes species in
Africa (5). YFV transmission has two epidemiologic pat-
terns, the sylvatic (jungle) and urban cycles. The primary
transmission cycle (sylvatic) involves nonhuman primates
and tree hole–breeding mosquitoes. The urban cycle is
defined by human involvement; humans are exposed to
infected mosquitoes, which leads to infection (5). YFV,
considered one of the reemerging human infections, is an
important public health problem with a case-fatality rate
that can exceed 50% in symptomatic patients (6). 
YFV has been successfully isolated from acute-phase
serum and liver samples by injection of suckling mice and
cell cultures (7), and recent infections can be confirmed
serologically by demonstrating immunoglobulin (Ig) M
antibody to YFV in serum samples with a specific IgM-
capture enzyme-linked immunosorbent assay (MAC-
ELISA) (8,9). Viral antigen can be detected in liver tissue
by using immunohistochemistry techniques, and viral
nucleic acid can be detected in serum or tissue samples
collected during the acute phase of illness by reverse tran-
scription–polymerase chain reaction (RT-PCR) (10).
Asafe and effective YFV vaccine, 17D, has been avail-
able since 1937. However, as it is not used universally,
probably because of cost or inefficient networks for vacci-
nation, the disease continues to occur in Africa and South
America (1). Periodic outbreaks of yellow fever in East
Africa have been reported since 1940 (11). The largest out-
break, estimated at 300,000 cases, occurred from 1960 to
1962 in Ethiopia (12). In 1966, yellow fever reappeared in
Arba-Minch, Ethiopia, east of Lake Abaya, in an area
unaffected by the outbreak of 1960. During the 1966 out-
break, 2,200 cases with 450 deaths were reported (13).
Seropositivity of 14% had been recorded in northern
Kenya (14,15), yet no outbreaks of yellow fever were
reported until 1992, when an epidemic emerged in north-
west Kenya, with at least 54 cases and 29 deaths (16,17). 
On May 5, 2003, Norwegian Church Aid reported to the
World Health Organization (WHO) office for southern
Sudan a suspected disease outbreak in Imatong, a moun-
tain range located in the southern part of Eastern
Equatoria, southern Sudan. The range extends northwards
to the town of Torit at 3,000 m above sea level. The moun-
tain is covered by tropical rain forest with rich flora and
fauna. Though the civil war has had a negative effect on
the ecosystem, the Lango people continue to live on the
eastern slopes of this mountain range. The total population
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ern Sudan, 2003, unpub. data). Their primary means of
livelihood is agriculture, although they also keep some
livestock. According to the report by WHO’s Early
Warning and Response Network (EWARN), which was
established in southern Sudan in 1999 to monitor disease
outbreaks, and the Norwegian Church Aid, the disease has
clinical signs and symptoms of a viral illness and has
caused the deaths of seven adults >30 years of age. On the
basis of clinical symptoms, a viral hemorrhagic fever was
suspected. On May 12, 2003, a team led by WHO arrived
in southern Sudan to investigate and verify the cause of the
outbreak. We report on laboratory investigations per-
formed and the identified causative agent. 
Materials and Methods
Collecting Human Serum
A case definition was established as follows: an illness
in a patient of any age with high fever, severe headache,
neck and back pain, possibly accompanied by vomiting,
abdominal pain, diarrhea, hematemesis, bloody diarrhea,
jaundice, and epistaxis. A total of 28 serum samples were
collected: 18 from patients with acute disease who met the
working case definition, 8 from patients with possible dis-
ease with headache and joint pain (patients 010, 013, 018,
020, 021, 022, 025, and 027), and 2 from convalescent
patients (patients 020 and 028). Patient details, including
their locations, are shown in the Table. Blood was collect-
ed in sterile evacuated clot activator Vacutainer tubes.
Thick and thin smears were made on microscope slides for
17 patients as indicated in the Table, and the serum sam-
ples were then separated in the admission facility and
stored in a liquid nitrogen dry shipper for transportation to
the WHO Collaborating Center for Arbovirus and Viral
Hemorrhagic Fever Reference and Research (CCAVH-
FRR) Laboratory at the Kenya Medical Research Institute
(KEMRI) in Nairobi, where they were frozen at –70°C
before testing. 
Serologic Testing
All the serum samples were heat-inactivated at 56°C
for 30 min and tested for antibodies specific to flavivirus-
es by MAC-ELISA (8,9). Briefly, the plates were coated
overnight at 4°C with anti-human IgM capture antibody
(Kirkegaard and Perry Laboratories, Gaithersburg, MD),
the plates were washed, and aliquots of test sera (positive
and negative controls) were added in separate wells at a
dilution of 1:400. After a 1-h incubation, the plates were
washed, and each serum and control sample was reacted
with sucrose-acetone extracted yellow fever antigen and
control antigen at optimal dilution. Positive samples were
detected with a commercially available monoclonal anti-
body against flaviviruses (6B6C-1) conjugated with horse-
radish peroxidase (Jackson Immunoresearch Laboratories,
West Grove, PA) according to the manufacturer’s protocol
and 2,2′-azino-bis(3-ethylbenthiazoline-6-sulfonic acid)
substrate (Kirkegaard and Perry Laboratories). Absorbance
was read at 405 nm. A presumptive diagnosis was made if
IgM antibody in the test sample had a higher optical den-
sity than the ratio between the positive and negative con-
trol antigens.
RT-PCR
All 28 serum samples were subjected to RT-PCR by
using a universal pair of primers for members of the genus
Flavivirus. Viral RNA was extracted directly from the
samples by using the QIAamp viral RNA isolation kit
(Qiagen, GmbH, Hilden, Germany). RT-PCR specific for
amplification of a 267-bp region of NS5 gene of flavivirus-
es was performed with 50 pmol of oligonucleotide primers
FU1 (TAC AAC ATG ATG GGA AAG AGA GAG AA)
and CFD2 (GTG TCC CAG CCG GCG GTG TCA TCA
GC) (18) and the Titan One Tube RT-PCR system (Roche
Diagnostics GmbH, Mannheim, Germany), according to
manufacturer’s instructions. The RT-PCR reactions were
performed on a Perkin Elmer GeneAmp 9700
Thermocycler (Applied Biosystems, Warrington,
England). The following cycling conditions were used:
50°C for 30 min followed by denaturation at 94°C for 3
min, 40 cycles of 94°C for 30 s, annealing at 55°C for 30
s, extension at 68°C for 30 s, and a final extension at 72°C
for 7 min. PCR products were resolved by using a 1.5%
agarose gel. A confirmatory RT-PCR was performed to
amplify a 670-bp region of the YFV prM, M, and E genes
with 50 pmol of oligonucleotide primers CAG (CTGTCC-
CAATCTCAGTCC) and YF7 (AATGCTTCCTTTCC-
CAAAT) (19). The following cycling conditions were
used: 50°C for 30 min followed by denaturation at 94°C
for 3 min, 40 cycles of 94°C for 30 s, annealing at 50°C for
30 s, extension at 68°C for 30 s, and a final extension at
72°C for 7 min. PCR products were then resolved on a
1.5% agarose gel. All the positive samples were exposed to
a second RNA extraction and RT-PCR to rule out the pos-
sibility of contamination. Positive amplicons obtained with
the Flavivirus-reactive primers were purified by excising
the 267-bp fragment from the agarose gel and purifying the
fragments with Qiagen gel purification kit (Qiagen) for
nucleotide sequence determination.
Nucleotide Sequencing
Gel-purified PCR products were quantitated, and the
partial nucleotide sequences of amplicons with a minimum
of 60 ng DNA/µL were determined by using Big Dye ter-
minator sequencing ready reaction kits with AmpliTaq
DNA polymerase FS (Applied Biosystems,  Foster City,
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each of the primers CFD2 and FU1 in a final volume of 20
µL with 30 ng of PCR product, 3.5 pmolof primer, and 4
µL of BigDye Terminators premix, according tothe manu-
facturer’s protocol. Briefly, the tubes were heated to 96°C
for 2 min, and the reaction mixture underwent 25 cycles of
30 s at 96°C,30 s at 50°C, and 4 min at 60°C. Excess Big
Dye Terminators were removed by precipitation with
absolute ethanol. The partial nucleotide sequence was
obtained with an Applied Biosystems 377 sequencer,
according to manufacturer’s instructions. 
A search performed on Basic Local Alignment Search
Tool (BLAST) (National Center for Biotechnology
Information, U.S. National Library of Medicine, Bethesda,
MD) suggested that the sequence obtained was amplified
from the yellow fever genome. This finding was confirmed
by aligning the sequence data with data from other known
flaviviruses retrieved from GenBank.
Virus Isolation
Aliquots of each of the serum samples were injected
intracerebrally into litters of eight newborn (24–48 hours
after birth) Swiss albino mice. The mice were observed
daily for signs of illness. Sick mice were euthanized, and a
preparation was made of 10% of the harvested mouse brain
suspension made in Eagle’s Maintenance Media with 2%
serum albumin, 2% glutamine, and 1% antibiotics (peni-
cillin, streptomycin, and amphotericin B) and centrifuged
at 3,000 rpm for 10 min. The clarified supernatant fluid
was filtered with a 0.45-µm syringe filter and injected
intracerebrally into a litter of suckling mice to confirm the
isolation. 
All the sera were diluted 1:10 in sterile phosphate-
buffered saline pH 7.4 (without magnesium and calcium),
and viral isolation attempts in Vero cell cultures were made
by injecting 100 µL of the diluted sample onto confluent
monolayer of Vero cells in 25-cm2 culture flasks. Flasks
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Table. History, location and results obtained from patients during yellow fever outbreak, Imatong, southern Sudan, May 2003
a 
Case no  Village  Sex  Age (y) 
Days after 








d  Lofi  Male  48  8  –  +  +/+  nd 
002
e  Locomo  Male  60  4  –  –  nd
e/–  – 
003
e  Tarafafa  Female  unknown  1  –  +  +/+  + 
004
e  Itohom  Female  12  Unknown  +  –  nd/–  + 
005
e  Tarafafa  Female  16  6  +  –  nd/–  + 
006
e  Locomo  Female  7  1  –  +  +/+  nd 
007
e  unknown  Male  unknown  Unknown  +  –  nd/–  + 
008
e  Lofi  Female  40  1  –  +  +/+  – 
009
d  Imatong  Female  35  Unknown  –  –  nd/–  nd 
010
e  Locomo  Female  15  Unknown  +  –  nd/–  + 
011
e  Locomo  Male  45  Unknown  +  –  nd/–  + 
012
e  Lofulang  Male  25  7  +  –  nd/–  nd 
013
e  Locomo  Female  8  1  –  +  +/+  nd 
014
e  Locomo  Male  60  Unknown  +  –  nd/–  – 
015
e  Ogolok  Male  42  Unknown  –  –  nd/–  – 
016
e  Locomo  Male  55  7  +  –  nd/–  – 
017
e  Tarafafa  Female  9  3  –  –  nd/–  – 
018
e  Lotodo  Female  3  Unknown  –  –  nd/–  – 
019
d  Imatong  Male  14  Unknown  –  –  nd/–  nd 
020
d  Imatong  Female  30  20  –  –  nd/–  + 
021
f  Lofi  Female  10  Unknown  +  –  nd/–  – 
022
f  Locomo  Male  25  Unknown  +  –  nd/–  nd 
023
f  Tarafafa  Male  60  Unknown  +  –  nd/–  nd 
024
e  unknown  Male  23  Unknown  –  –  nd/–  – 
025
f  Locomo  Female  40  Unknown  +  –  nd/–  nd 
026
e  Lofong  Female  16  Unknown  –  –  nd/–  – 
027
e  Locomo  Female  4  Unknown  +  –  nd/–  nd 
028
f  Itede  Female  23  21  –  –  nd/–  nd 
alg,immunoglobin; RT-PCR, reverse transcriptase-polymerase chain reaction; MPS, mucopolysacchariodisis; nd, not done.
 
bSpecimens were tested using primers reactive with genus Flavivirus and with a second set of primers specific to yellow fever virus. Nucleotide sequences 
were also determined. 
cMalaria parasite smear.  
dFatal case.  
eNo outcome for cases due to inaccessibility. 
fRecovered. were incubated at 37°C and observed daily for evidence of
cytopathogenic effect (CPE). After CPE was evident, the
supernatant fluid was clarified by centrifugation at 3,000
rpm for 10 min. Viral RNA was extracted from both the
10% brain suspension from sick mice and from the clari-
fied cell culture media and screened for flavivirus and
YFV viral nucleic acid RNA by RT-PCR as described pre-
viously. 
Differential Diagnosis
IgM antibody tests were performed on all the samples
to exclude recent exposure to Ebola virus, Marburg virus,
Crimean-Congo hemorrhagic fever virus, West Nile virus,
dengue virus, chikungunya virus, Sindbis virus, and Rift
Valley fever virus. In addition, Ebola virus was excluded
by using an antigen capture ELISA. PCR was performed to
exclude the following pathogens: Crimean-Congo hemor-
rhagic fever virus, Rift Valley fever virus, Ebola virus,
Marburg virus, rickettsia, leptospira, brucella, and mem-
bers of the genus Alphavirus  and  Bunyavirus. For 17
patients, thick blood smears were checked for Borrelia
spp. and thin blood smear slides were checked for malari-
al parasites.
Results
On May 17, 2003, serologic tests and RT-PCR per-
formed at the WHO CCAVHFRR at KEMRI identified
YFV as the causative agent of the outbreak in southern
Sudan. The diagnosis was supported by subsequent gene
sequencing of the amplicons and isolation of the virus. The
results obtained are summarized in the Table. Duplicate
samples submitted to the Special Pathogens Unit at the
National Institute for Communicable Diseases, South
Africa, confirmed an outbreak of yellow fever. 
Detecting IgM Antibody to Flaviviruses
RT-PCR and Nucleotide Sequencing
Samples from five patients were positive for flavivirus
viral nucleic acid and subsequently were positive for yel-
low fever viral nucleic acid with primers specific for YFV.
Analysis of the nucleotide sequences obtained with the fla-
vivirus primers confirmed that the amplicons were from
the NS5 region of the yellow fever genome (phylogeny has
been performed separately). The serum samples that were
positive by PCR were collected from patients on day 1
after onset of illness except for one sample collected on
day 8 from a patient with a fatal infection. 
Viral Isolation
YFV was isolated, in both suckling mice and cell cul-
tures, from five patients from whom PCR products were
obtained. Virus isolation attempts on the remaining 23
serum samples from both suckling mice and Vero cell cul-
ture were negative.
Differential Diagnosis
The sera were all negative by using various tests as
described for Ebola virus, Marburg virus, Crimean-Congo
hemorrhagic fever virus, West Nile virus, dengue virus,
chikungunya virus, Sindbis virus, Rift Valley fever virus,
rickettsia, leptospira, brucella, and members of the genus
Alphavirus and Bunyavirus. The thick smears were nega-
tive for Borrelia by Giemsa staining. However, malaria
parasites were demonstrated in thin smears from 7 of 17
patients tested; 6 of the patients with malaria also had evi-
dence of YFV infection.
Discussion
Samples from 28 patients were collected from various
villages in the Imatong region as follows: 10 were from
Locomo village, 3 from Lofi, 4 from Tarafafa, 3 from
Imatong, and 1 each from Itohom, Lofulung, Ogolok,
Lotodo, Lofong, and Itede; 2 were from unknown loca-
tions. A total of 18 patients had possible YFV infections
demonstrated by detection of IgM antibody, while 5
patients were confirmed as positive for YFV by RT-PCR
and virus isolation. Antibody was not demonstrable in the
five patients who had positive RT-PCR results; in 4
patients, the specimens were collected too early (day 1) for
antibody to be detectable. In patient 001 (Table), the spec-
imen was collected on day 8 from a patient with a fatal
infection. The patient was comatose and in the late stages
of infection; antibodies were not found, possibly because
of a failure to produce antibodies for a variety of factors,
such as nutritional status, age, and immune status. This
finding demonstrates the importance of using both modal-
ities in the diagnosis of acute YFV infection.
Plasmodium, the causative agent of malaria, was
demonstrated in six patients who were positive for YFV.
This finding demonstrates that co-infection with malaria
and YFV is possible. Therefore, malaria should not be
assumed as the etiologic agent of a disease outbreak sole-
ly based on positive screens, without first excluding other
causes. 
YFV maybe be enzootic in the Imatong Mountains, yet
outbreaks have not been previously recorded in this region.
Political unrest and population movement of highly sus-
ceptible (unvaccinated) people within the Imatong
Mountains might have been a predisposing factor for the
YFV outbreak in this region. During the civil unrest, large
populations of monkeys were reportedly seen. As they
became more dependent on human crops for food, the
monkeys came closer to human habitations. Weather fac-
tors might have also contributed to the timing of the out-
break. The months of March to May 2003 were the rainy
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tain region. The persistent downpours may have resulted in
high vector populations. With no history of human yellow
fever in the outbreak zone, the monkey population must be
adequate to support continued circulation of the virus in
the sylvatic cycle. A combination of these factors likely
contributed to the timing of the outbreak.
The early detection of this outbreak was due to
EWARN, a WHO-facilitated network that brings together
several healthcare providers and laboratories. One of the
objectives of EWARN is the early detection and response
to outbreaks, such as this one. The rapid response to this
outbreak of YFV and subsequent laboratory-based diagno-
sis clearly demonstrate that an efficient surveillance sys-
tem can lead to quickly detecting outbreaks and
appropriate intervention, potentially saving many lives. At
the time of this writing, 80% of the population at risk in
Imatong had been vaccinated, with the campaign extend-
ing to Torit County and neighboring counties. Vaccination
in Torit County had covered 51% of the population at risk
(98,705). 
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